Background: Oxaliplatin, a new DACH-platinum compound, has provided high response rates both in untreated and 5-FU-resistant patients. Aim: to define the feasibility and toxicity profile of Oxaliplatin administered as a continuous hepatic aterial infusion. Patients and Methods: Seventeen patients with pretreated metastatic liver colorectal cancer were treated with Oxaliplatin 20 mg/m 2/day by HACI x 5 days every 3 weeks. Results: Toxicity grade 3 included pain (4 out of 17), asthenia (1 out of 17) and nausea (1 out of 17). Abdominal pain grade 4 (WHO) was noted in only one patient. Overall, severe abdominal pain (main dose-limiting toxicity) was observed in 41% of patients and no chemical hepatitis and sclerosing cholangitis pain-related was proven by an endoscopic retrograde cholangiography. The response rate was not a primary end-point; nonetheless among 15 evaluable patients we observed partial responses (PR) in 7 patients (46%) and stable disease (SD) in 21% of cases for an overall tumor growth control of 67%. Progression to disease (PD) was 33%. Following chemotherapy, one patient underwent surgical removal of residual metastases, with curative intent. The 1-year survival rate was 64%. The median duration of survival was 19 months. The median delay to hepatic progression was 10 months. Conclusion: Further studies are required to define the role of HACI Oxaliplatin, the schedule of administration (bolus vs continuous infusion) and the combination, also in this setting, with fluoropyrimidines.

Hepatic arterial continuous infusion (HACI) of oxaliplatin in patients with unresectable liver metastases from colorectal cancer / A., Mancuso; R., Giuliani; C., Accettura; M., Palma; G., D'Auria; F., Cecere; L., Paoluzzi; Bezzi, Mario; B., Massidda; Cortesi, Enrico. - In: ANTICANCER RESEARCH. - ISSN 0250-7005. - STAMPA. - 23:2 C(2003), pp. 1917-1922.

Hepatic arterial continuous infusion (HACI) of oxaliplatin in patients with unresectable liver metastases from colorectal cancer

BEZZI, Mario;CORTESI, Enrico
2003

Abstract

Background: Oxaliplatin, a new DACH-platinum compound, has provided high response rates both in untreated and 5-FU-resistant patients. Aim: to define the feasibility and toxicity profile of Oxaliplatin administered as a continuous hepatic aterial infusion. Patients and Methods: Seventeen patients with pretreated metastatic liver colorectal cancer were treated with Oxaliplatin 20 mg/m 2/day by HACI x 5 days every 3 weeks. Results: Toxicity grade 3 included pain (4 out of 17), asthenia (1 out of 17) and nausea (1 out of 17). Abdominal pain grade 4 (WHO) was noted in only one patient. Overall, severe abdominal pain (main dose-limiting toxicity) was observed in 41% of patients and no chemical hepatitis and sclerosing cholangitis pain-related was proven by an endoscopic retrograde cholangiography. The response rate was not a primary end-point; nonetheless among 15 evaluable patients we observed partial responses (PR) in 7 patients (46%) and stable disease (SD) in 21% of cases for an overall tumor growth control of 67%. Progression to disease (PD) was 33%. Following chemotherapy, one patient underwent surgical removal of residual metastases, with curative intent. The 1-year survival rate was 64%. The median duration of survival was 19 months. The median delay to hepatic progression was 10 months. Conclusion: Further studies are required to define the role of HACI Oxaliplatin, the schedule of administration (bolus vs continuous infusion) and the combination, also in this setting, with fluoropyrimidines.
2003
arterial infusion; colorectal cancer; liver metastasis; metastatic liver; oxaliplatin
01 Pubblicazione su rivista::01a Articolo in rivista
Hepatic arterial continuous infusion (HACI) of oxaliplatin in patients with unresectable liver metastases from colorectal cancer / A., Mancuso; R., Giuliani; C., Accettura; M., Palma; G., D'Auria; F., Cecere; L., Paoluzzi; Bezzi, Mario; B., Massidda; Cortesi, Enrico. - In: ANTICANCER RESEARCH. - ISSN 0250-7005. - STAMPA. - 23:2 C(2003), pp. 1917-1922.
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/441428
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 40
  • ???jsp.display-item.citation.isi??? 34
social impact